Noctrix Health

What Noctrix Health does

Noctrix Health is a medical device company headquartered in Pleasanton, California that developed Nidra Tonic Motor Activation (TOMAC) Therapy, the first FDA-authorized non-invasive wearable neuromodulation device for adults with moderate-to-severe Restless Legs Syndrome (RLS). The therapy delivers therapeutic stimulation to alleviate RLS symptoms without disrupting sleep, with reported symptom relief in as little as 30 minutes. It is prescription-based and indicated for drug-refractory RLS patients who have not found adequate relief with pharmacological treatments. The device received FDA Breakthrough Device Designation in June 2020 and De Novo authorization in April 2023, supported by 10 peer-reviewed publications, 5 completed clinical trials, and 10,000+ nights of clinical data; it was subsequently included in AASM Clinical Practice Guidelines in 2025.

The company generated revenue through prescription hardware sales distributed via Home Medical Equipment (HME/DME) providers and sleep physician referrals, with CMS reimbursement codes established in October 2024. At the time of acquisition, Noctrix was generating approximately $24 million in annual run rate revenue with higher gross margins than ResMed's core business. The company was acquired by ResMed Inc. for approximately $340 million on June 1, 2026, becoming a wholly owned subsidiary integrated into ResMed's connected health ecosystem (AirView, serving 28 million patients across 140+ countries). Prior to acquisition, Noctrix had raised approximately $73.5 million across multiple financing rounds, including a $40 million Series C in 2024 led by Sectoral Asset Management with participation from Angelini Ventures, Asahi Kasei, OrbiMed, ResMed, and Treo Ventures.

Name

Noctrix Health

Legal name

Noctrix Health, Inc.

Website

https://noctrixhealth.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

11–50 employees

Short description

Noctrix Health is a medical device company that developed Nidra TOMAC Therapy, the first FDA-authorized non-invasive wearable neuromodulation device for moderate-to-severe Restless Legs Syndrome. Acquired by ResMed for $340 million in June 2026.

Ownership category

akta.pro rank

Product category

Wearable Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)

Keywords

• Wearable neuromodulation devices
• Restless legs syndrome treatment
• Non-invasive neurostimulation therapy
• Medical wearable therapeutics
• Sleep disorder medical devices

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Nidra Device and Therapy Sales: Noctrix generates revenue through the sale of its Nidra wearable neuromodulation device and associated supplies/therapy. Annual run rate revenue was approximately $24 million at the time of ResMed acquisition. The therapy has higher gross margins than ResMed's core business.
2. CMS Reimbursement: CMS issued new dedicated HCPCS codes along with payments for Nidra and supplies starting October 2024, enabling reimbursement through healthcare insurance pathways.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Noctrix Health develops and sells the Nidra Tonic Motor Activation (TOMAC) Therapy, a prescription-only, non-invasive, drug-free wearable neuromodulation device indicated for adults with moderate-to-severe Restless Legs Syndrome (RLS) who have not found sufficient relief with drug therapy. The device delivers therapeutic stimulation to alleviate RLS symptoms in as little as 30 minutes without disrupting sleep, and is supported by CMS reimbursement codes and payment pathways established in October 2024.

Product overview

Noctrix Health offers a single core product — the Nidra Tonic Motor Activation (TOMAC) Therapy — a prescription wearable neuromodulation device indicated for adults with moderate-to-severe restless legs syndrome (RLS) who have not found sufficient relief with drug therapy. The product received FDA De Novo classification in April 2023 and launched commercially in July 2023, with CMS reimbursement codes established in October 2024. The therapy is supported by 10 peer-reviewed publications, 5 completed clinical trials, and inclusion in AASM clinical guidelines. ResMed acquired Noctrix Health for $340 million in June 2026, integrating it as a wholly owned subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

• Nidra: Nidra Tonic Motor Activation (TOMAC) Therapy - a non-invasive wearable therapy for drug-refractory Restless Legs Syndrome that received FDA De Novo classification.

Products and services

• Nidra Tonic Motor Activation (TOMAC) Therapy Non-invasive, drug-free, prescription-only wearable neuromodulation device that delivers symptom relief for adults with moderate-to-severe Restless Legs Syndrome (RLS) in as little as 30 minutes using Tonic Motor Activation technology, without disrupting sleep. The device is indicated for RLS patients who have not found sufficient relief with drug therapy and is supported by CMS reimbursement codes.

Quantifiable outcome

• Relief from RLS symptoms in as little as 30 minutes
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• ResMedcoreStrategic or Co-development Partner · 1 June 2026ResMed completed acquisition of Noctrix Health for $340 million, making it a wholly owned subsidiary. ResMed plans to integrate Noctrix's wearable neuromodulation technology into its connected devices and digital health offerings, expanding beyond core CPAP business into adjacent sleep disorders.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• ElectroCore: ElectroCore develops non-invasive vagus nerve stimulation (nVNS) devices for neurological and inflammatory conditions. It is comparable as a non-invasive, wearable neuromodulation peer targeting chronic conditions through prescription-based distribution.
• Cala Health: Cala Health develops wearable neuromodulation devices for essential tremor and other chronic conditions, making it a comparable peer in the non-invasive, wearable, prescription therapeutic neurostimulation category targeting chronic neurological disorders.

Direct peers

• Axonics: Axonics develops sacral and pudendal neuromodulation implants for incontinence, comparable as a neuromodulation device company with similar regulatory pathway (FDA-authorized implantable neurostim). Both share the HME/DME distribution model and CMS reimbursement dependency.
• Inspire Medical Systems: Inspire Medical Systems manufactures an implantable neurostimulation device for obstructive sleep apnea, the most direct analog to Noctrix's neuromodulation approach for sleep disorders. Both companies target FDA-regulated, prescription-based neurostimulation therapies distributed through sleep physicians.
• Nevro: Nevro manufactures spinal cord stimulation (SCS) systems for chronic pain, a peer in prescription neuromodulation with similar FDA clearance dynamics, clinical evidence requirements, and physician-channel distribution model.
• NeuroPace: NeuroPace develops implantable responsive neurostimulation for epilepsy, making it a peer in the FDA-regulated neuromodulation device space. Both companies pursue prescription neurostimulation therapies targeting chronic neurological conditions with regulatory exclusivity as a core moat.

Broad incumbents

• LivaNova: LivaNova is a neuromodulation and cardiac surgery device company (vagus nerve stimulation, deep brain stimulation), making it a broad incumbent in implantable neuromodulation. Notably, LivaNova was an early investor in Noctrix and shares overlap in clinical and regulatory pathways.
• ResMed: ResMed is the global leader in sleep-disordered breathing devices (CPAP) and acquired Noctrix for $340M. While now the parent company, ResMed is also the dominant incumbent in the sleep therapy distribution channels (HME/DME, sleep physician network) that Noctrix's commercial model depends on.
• Philips Respironics: Philips Respironics is a major incumbent in sleep and respiratory care devices, including CPAP machines. It represents a broad sleep therapy incumbent with overlapping distribution channels and end customers (sleep physicians, HME providers, RLS patients with comorbid sleep apnea).
• Fisher & Paykel Healthcare: Fisher & Paykel Healthcare is a leading manufacturer of sleep apnea and respiratory care devices, competing in adjacent sleep therapy hardware categories distributed through similar HME/DME channels and physician networks.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/noctrix-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noctrix Health